SGLT-2 Inhibitors Linked to Lower Epilepsy Risk in Type 2 Diabetes: Study Dr. Shravani Dali21 May 2025 9:15 AM ISTA recent population-based study published in Diabetes Care suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors, commonly prescribed for...
GLP-1 diabetes drugs not linked to heightened suicidality risk: Study Dr. Kamal Kant Kohli27 Feb 2025 9:00 AM ISTUse of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with two other groups of...
SGLT2 Inhibitors and GLP-1 Receptor Agonists Linked to Fewer COPD Exacerbations in diabetes patients with COPD: JAMA Dr Riya Dave17 Feb 2025 8:45 AM ISTResearchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists...
Elective Peri-Operative Management of Patients on GLP-1, GIP Agonists & SGLT-2 Inhibitors: Multidisciplinary Consensus Released Nidhi Srivastava11 Feb 2025 11:34 AM ISTUK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the Association of British Clinical...
SGLT-2 drug plus moderate calorie restriction achieves higher diabetes remission: Study Dr. Kamal Kant Kohli23 Jan 2025 9:15 AM ISTAdults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside...
SGLT2 Inhibitors might prevent dementia in Diabetes Patients, reveals research Dr. Kamal Kant Kohli30 Aug 2024 9:00 AM ISTSodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes might prevent dementia, providing greater benefits with longer...
Two medication classes reduced cardiovascular and liver events in people with type 2 diabetes, suggests study Dr. Kamal Kant Kohli12 Jun 2024 9:45 AM ISTGLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications...
Use of SGLT-2 inhibitors for HF management safe and well tolerated in adult congenital heart disease patients: Study Medha Baranwal20 Feb 2024 6:30 PM ISTUSA: A recent study showed that sodium-glucose transporter 2 inhibitors (SGLT-2i) use appears safe and well tolerated in a small cohort of the adult...
SGLT-2 inhibitors reduce adverse CV outcomes related to intra-stent restenosis in patients with type 2 diabetes Medha Baranwal11 March 2023 11:00 AM ISTItaly: Treatment with SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM) is linked with a reduced risk of intra-stent restenosis...
SGLT-2 inhibitors improve exercise capacity and QoL in patients with chronic HF Dr Kartikeya Kohli21 Feb 2023 10:45 AM ISTChina: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve health-related quality of life (HRQoL) and exercise capacity in chronic heart...
Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis Dr Kartikeya Kohli10 Feb 2023 11:30 AM ISTSwitzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Dapagliflozin improves myocardial reserve flow in type 2 diabetes patients: DAPAHEART Trial Dr. Kamal Kant Kohli13 Sept 2022 11:00 AM ISTSGLT-2 inhibition in type 2 diabetes patients increases myocardial flow reserve (MFR). ITALY: According to a recent study published in the...
